Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review

Surgeon

Volumn 10, Issue 1, 2012, Pages 36-42

  McLeod, Niall M H ^a   Brennan, Peter A ^b   Ruggiero, Salvatore L ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c New York Center for Oral and Maxillofacial Surgery   (United States)

Author keywords

Bisphosphonate; Dentistry; Mandible; Maxilla; Osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

HISTORY; HUMAN; JAW OSTEONECROSIS; PRACTICE GUIDELINE; REVIEW; UNITED KINGDOM;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; DIPHOSPHONATES; GREAT BRITAIN; HISTORY, 21ST CENTURY; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84855474528     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2011.09.002     Document Type: Review

References (50)

1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 2002, 19(1):80-100.
2. Rogers M.J.S., Gordon H.L., Benford F.P., Coxon S.P., Luxman J., Monkkonen J., et al. Cellular and molecular mechanism of action of bisphosphonates. Cancer 2000, 88(Suppl. 12):2961-2978.
3. Wood J., Bonjean K., Reutz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302(3):1055-1061.
4. Santini D., Vespasiani Gentilucci U., Vincenzi B., Picardi A., Vasaturo F., La Cesa A., et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003, 14:1468-1476.
5. Jeffcoat M.K., Cizza G., Shih W.J., Genco R., Lombardi A. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol 2007, 9(3):70-76.
6. Hellstein J.W., Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 2005, 63:682-689.
7. Demerjian N., Bolla G., Spreux A. Severe oral ulceration induced by alendronate. Clin Rheumatol 1999, 18:349-350.
8. De Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., et al. Oesophagitis associated with the use of alendronate. N Eng J Med 1996, 355:1016-1021.
9. Ruggiero S.L. Bisphosphonate related osteonecrosis of the jaw (BRONJ); initial discovery and subsequent development. J Oral Maxillofac Surg 2009, 67(Suppl. 1):13-18.
10. Marx R.E. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:115-118. [letter].
11. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003, 21(22):4253-4254.
12. Mehrotra B., Fantasia J., Nissel Horrowitz S., Vinarsky S., Sheth M., Ruggiero S. Osteonecrosis of the maxilla; an unusual complication of prolonged bisphosphonate therapy; a case report. Proc Am Soc Clin Oncol 2003, 22:795. (Abstract 3194).
13. Rosenberg T.J., Ruggiero S. Osteonecrosis of the jaw associated with the use of bisphosphonates. J Oral Maxillofac Surg 2003, 61(Suppl. 1):60.
14. Wang J., Goodger N.M., Pogrel M.A. Osteonecrosis of the jaw associated with cancer chemotherapy. J Oral Maxillofac Surg 2003, 61:1104-1107.
15. Mcleod NMH, Patel V, Kusanale A, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw - a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg doi:10.1016/j.bjoms.2010.08.005.
16. Ruggiero S., Gralow J., Marx Re, Hoff A.O., Schubert M.M., Huryn J.M., et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006, 2(1):7-14.
17. Ruggiero S.L., Dodson T.B., Assael L.A., Landesberg, Marx R.E., Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009, 67:2-12.
18. Colella G., Campisi G., Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws - 2009 update; the need to refine the BONJ definition. J Oral Maxillofac Surg 2009, 67:2698.
19. Bauss F., Pfister T., Papapoulos S. Ibandronate uptake in the jaw is similar to longbones and vertebrae in the rat. J Bone Miner Metab 2008, 26:406-408.
20. Otto S., Hafner S., Mast G., Tischer T., Volkmer E., Schieker M., et al. Bisphosphonate related osteonecrosis of the jaw: is pH the missing part of the puzzle?. J Oral Maxillofac Surg 2010, 68:1158-1161.
21. Ruggiero S.L., Fantasia J., Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Path Oral Radiol Endod 2006, 102(4):433-441.
22. Weitzman R., Sauter N., Eriksen E.F., Tarassoff P.G., Lacerna L.V., Dias R., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit Rev Oncol Hematol 2007, 62:148-152.
23. McMahon R.E., Bouquot J.E., Glueck C.J., Griep J.A., Adams W.R., Splonik K.J., et al. Staging bisphosphonate-related osteonecrosis of the jaws should include early stages of the disease. J Oral Maxillofac Surg 2007, 65:1899-1990.
24. Kwon Y., Kim D., Ohe J., Yoo J., Walter C. Correlation between serum c-terminal cross-linking telopeptide of type 1 collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67:2644-2648.
25. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587.
26. Stumpe M.R., Chandra R.K., Yunus F., Samant S. Incidence and risk factors of bisphosphonate associated osteonecrosis of the jaws. Head Neck 2009, 31:202-206.
27. American Dental Association Council on Scientific Affairs Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006, 137(8):1144-1150.
28. Mavrokokki T., Stein B., Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaw in Australia. J Oral Maxillofac Surg 2007, 65:415-423.
29. Williamson R.A. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010, 39:251-255.
30. Marx R.E., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
31. Montebugnoli L., Felicetti L., Gissi D.B., Pizzigallo A., Pelliccioni G.A., Marchetti C. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 104:473-477.
32. Bocanegra Pérez S., Vincente Barrero M., Sosa Hernández M., Knezevic M., Castallano Navarro J.M., Rodríguez Millares J. Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment. Med Oral Patol Oral Cir Bucal 2008, 13(12):E770-E773.
33. Thumbigere-Math V., Sabino M.A., Gopalakrishnan R., Huckabay S., Dudek A.Z., Basu S., et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009, 67:1904-1913.
34. Bagán J., Blade J., Cozar J.M., Constela M., García Sanz R., Gómez Veiga G., et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 2007, 12:E336-E340.
35. Patel V, McLeod NMH, Roger SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw - a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg doi:10.1016/j.bjoms.2010.05.
36. Tubiana-Hulin M., Spielmann M., Roux C., Campone M., Zelek L., Gligorov J., et al. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol 2009, 71(1):12-21.
37. Markose G., Mackenzie F.R., Currie W.J.R., Hislop W.S. Bisphosphonate osteonecrosis: a protocol for surgical management. Br J Oral Maxillofac Surg 2009, 47:294-297.
38. Marx R.E. Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67(Suppl. 1):107-119.
39. Engroff S.L., Coletti D. Bisphosphonate related osteonecrosis of the palate: report of a case managed with free tissue transfer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 105:580-582.
40. McLeod N.M., Davies B.J., Brennan P.A. Bisphosphonate osteonecrosis of the jaws; an increasing problem for dental practitioner. Br Dent J 2007, 203:641-644.
41. Dimopoulos M.A., Kastritis E., Bamia C., Melakopoulos I., Gika D., Roussou M., et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009, 20:117-120.
42. Ripamonti C.I., Maniezzo M., Campa T., Fagnoni E., Brunelli C., Saibene G., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: the experience of the National Cancer Institute of Milan. Ann Oncol 2009, 20:137-140.
43. Edwards B.J., Hellstein J.W., Jacobsen P.L., Kaltman S., Mariotti A., Migliorati C.A. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy. J Am Dent Assoc 2008, 139:1674-1677.
44. American Association of Endodontists Position Statement: endodontic implications of bisphosphonate-associated osteonecrosis of the jaws 2006, http://www.aae.org/dentalpro/guidelines.htm.
45. Grant B.T., Amenedo C., Freeman K., Krau R.A. Outcomes ofplacing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008, 866:223-230.
46. Marx R.E., Cillo J.E., Ulloa J.J. Oral bisphosphonate induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 2007, 65:2397-2410.
47. Kuncher R., Need A., Hughes T., Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67:1167-1173.
48. Montefusco V., Gay F., Soina F., Miceli R., Maniezzo M., Teresa Ambrosini M., et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008, 49(11):2156-2162.
49. McLeod N.M.H., Davies B.J.B., Brennan P.A. Management of patients at risk of bisphosphonate osteonecrosis in maxillofacial surgery units in the UK. Surgeon 2009, 7:18-23.
50. Malden N., Beltes C., Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Bt Dent J 2009, 206:93-98.